Tags : NAV AAV9 vector

Pfizer Signs a License Agreement with Regenxbio for its NAV

Shots: Regenxbio to receive up front, development and commercial milestone and royalties on sales of products. Pfizer to get non-exclusive WW license with rights to sublicense Regenxbio’s NAV AAV9 vector to develop & commercialize gene therapies for Friedreich’s ataxia The focus of the agreement is to strengthen Regenxbio’s intellectual property portfolio and the potential of NAV […]Read More

RegenxBio and Rocket Signs Exclusive Worldwide License Agreement for NAV

Shots: RegenxBio to receive $7M upfront, milestones payments plus royalties on net sales. Rocket to get exclusive worldwide rights for RegenxBio’s NAV AAV9 Vector to develop and commercialize gene therapies for Danon disease Rocket also has exclusive option to add two additional NAV AAV vectors for Danon disease, for duration of four years REGENXBIO’s NAV […]Read More